Immunogenomics and Inflammation Research Unit EA 4130, University of Lyon.
Cancer Research Center Lyon, INSERM U1052 and CNRS 5286, University of Lyon, Lyon, France.
Clin Exp Immunol. 2018 Aug;193(2):221-233. doi: 10.1111/cei.13140. Epub 2018 May 31.
The proinflammatory cytokines interleukin (IL)-17 and tumour necrosis factor (TNF)-α are targets for treatment in many chronic inflammatory diseases. Here, we examined their role in liver inflammatory response compared to that of IL-6. Human hepatoma cells (HepaRG, Huh7.5 and HepG2 cells) and primary human hepatocytes (PHH) were cultured with IL-6, IL-17 and/or TNF-α. To determine the contribution of the IL-6 pathway in the IL-17/TNF-α-mediated effect, an anti-IL-6 receptor antibody was used. IL-17 and TNF-α increased in synergy IL-6 secretion by HepaRG cells and PHH but not by Huh7.5 and HepG2 cells. This IL-17/TNF-α synergistic cooperation enhanced the levels of C-reactive protein (CRP) and aspartate aminotransferase (ASAT) in HepaRG cell and PHH cultures through the induction of IL-6. IL-17/TNF-α also up-regulated IL-8, monocyte chemoattractant protein (MCP)-1 and chemokine (C-C motif) ligand 20 (CCL20) chemokines in synergy through an IL-6-independent pathway. Interestingly, first exposure to IL-17, but not to TNF-α, was crucial for the initiation of the IL-17/TNF-α synergistic effect on IL-6 and IL-8 production. In HepaRG cells, IL-17 enhanced IL-6 mRNA stability resulting in increased IL-6 protein levels. The IL-17A/TNF-α synergistic effect on IL-6 and IL-8 induction was mediated through the activation of extracellular signal-regulated kinase (ERK)-mitogen-activated protein kinase, nuclear factor-κB and/or protein kinase B (Akt)-phosphatidylinositol 3-kinase signalling pathways. Therefore, the IL-17/TNF-α synergistic interaction mediates systemic inflammation and cell damage in hepatocytes mainly through IL-6 for CRP and ASAT induction. Independently of IL-6, the IL-17A/TNF-α combination may also induce immune cell recruitment by chemokine up-regulation. IL-17 and/or TNF-α neutralization can be a promising therapeutic strategy to control both systemic inflammation and liver cell attraction.
促炎细胞因子白细胞介素 (IL)-17 和肿瘤坏死因子 (TNF)-α 是许多慢性炎症性疾病治疗的靶点。在这里,我们研究了它们在肝脏炎症反应中的作用与白细胞介素 6 (IL-6) 的比较。用人肝癌细胞 (HepaRG、Huh7.5 和 HepG2 细胞) 和原代人肝细胞 (PHH) 培养白细胞介素 6、白细胞介素 17 和/或肿瘤坏死因子-α。为了确定 IL-6 通路在白细胞介素 17/TNF-α 介导的作用中的贡献,使用了抗白细胞介素 6 受体抗体。白细胞介素 17 和肿瘤坏死因子-α协同增加 HepaRG 细胞和 PHH 中的白细胞介素 6 分泌,但 Huh7.5 和 HepG2 细胞则不然。这种白细胞介素 17/TNF-α 的协同合作通过诱导白细胞介素 6 增加了 HepaRG 细胞和 PHH 培养物中 C-反应蛋白 (CRP) 和天冬氨酸氨基转移酶 (ASAT) 的水平。白细胞介素 17/TNF-α 还通过一种不依赖白细胞介素 6 的途径协同上调白细胞介素 8、单核细胞趋化蛋白 1 (MCP)-1 和趋化因子 (C-C 基序) 配体 20 (CCL20) 趋化因子。有趣的是,首先暴露于白细胞介素 17 而不是肿瘤坏死因子-α,对于启动白细胞介素 17/TNF-α 协同作用对白细胞介素 6 和白细胞介素 8 产生至关重要。在 HepaRG 细胞中,白细胞介素 17 增强了白细胞介素 6 mRNA 的稳定性,导致白细胞介素 6 蛋白水平升高。白细胞介素 17A/TNF-α 对白细胞介素 6 和白细胞介素 8 诱导的协同作用是通过细胞外信号调节激酶 (ERK)-丝裂原活化蛋白激酶、核因子-κB 和/或蛋白激酶 B (Akt)-磷酸肌醇 3-激酶信号通路的激活介导的。因此,白细胞介素 17/TNF-α 的协同相互作用主要通过白细胞介素 6 诱导 CRP 和 ASAT 诱导来介导肝细胞中的全身炎症和细胞损伤。独立于白细胞介素 6,白细胞介素 17A/TNF-α 组合也可能通过趋化因子的上调诱导免疫细胞募集。白细胞介素 17 和/或肿瘤坏死因子-α 的中和可能是控制全身炎症和肝细胞趋化的一种很有前途的治疗策略。